Mekhail Extension of the Motzer Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Favorable Risk0–1
- Intermediate Risk2–2
- Poor Risk3–6
The Mekhail Extension of the Motzer Score calculator is designed for bedside predicting survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic.
Clinical Guidelines & Evidence
Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors
Clinical Indication
The Mekhail Extension of the Motzer Score is indicated for bedside clinical practice to support Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Score = Sum of present risk factors (each factor = 1 point if present)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| ldh_elevated | string | Yes | LDH > 1.5x upper limit of normal (ULN). Normal ULN is typically 140 U/L |
| hemoglobin_low | string | Yes | Hemoglobin < lower limit of normal (typically <12 g/dL) |
| corrected_calcium_high | string | Yes | Corrected serum calcium > 10 mg/dL (2.5 mmol/L) |
| time_to_treatment_less_than_1_year | string | Yes | Time from initial diagnosis to systemic treatment < 1 year |
| prior_radiotherapy | string | Yes | Prior treatment with radiation therapy |
| metastatic_sites_2_or_more | string | Yes | ≥2 sites of metastasis |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Favorable Risk | 0-1 risk factors |
| 2–2 | Intermediate Risk | 2 risk factors |
| 3–6 | Poor Risk | ≥3 risk factors |
Evidence-Based References (EBM)
- Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005 Feb 1;23(4):832-41. doi: 10.1200/JCO.2005.05.179.DOI: 10.1200/JCO.2005.05.179
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.DOI: 10.1200/JCO.1999.17.8.2530
Related calculators
- Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)
- Mekhail Extension of the Motzer Score
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients
- Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes
- Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score